th 44 Annual Raymond James Institutional Investors Conference Orlando • March 2023 ...

Medtronic plc (NYSE:MDT) Cowen 43rd Annual Healthcare Conference March 6, 2023 10:30 AM ET Company Participants Karen Parkhill - Executive Vice President and Chief Financial Officer Conference Call Participants Josh Jennings - Cowen and Company Josh Jennings We are moving down the medical devices track here at the TD Cowen 43rd Annual Healthcare Conference. We're excited to have Karen Parkhill, the Chief Financial Officer, Executive Vice President at Medtronic, the largest medical device company in the worl ...

rd 43 Annual TD Cowen Healthcare Conference Boston • March 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 27, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R ...

Not started Work in progress Update complete Medtronic plc Q3 FY23 Earnings presentation ...

Medtronic plc (NYSE:MDT) Q3 2023 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Ryan Weispfenning - Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Bob White - Executive Vice President and President, Medical Surgical Portfolio Brett Wall - Executive Vice President and President, Neuroscience Portfolio Que Dallara - Executive Vice President and President, Diabetes Operating Unit Sean Salmon - Executive Vice President ...

41st annual J.P. Morgan healthcare conference Geoff Martha, Chairman and CEO January 9, 2023 San Francisco Forward-looking statements, non-GAAP financial measures, and comparisons Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and ...

Medtronic plc (NYSE:MDT) J.P. Morgan 41st Annual Healthcare Conference January 9, 2023 11:15 AM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Que Dallara - Executive Vice President and President, Diabetes Operating Unit Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Conference Call Participants Robbie Marcus - J.P. Morgan Operator Thanks, everyone. We'll get started here. I'm Robbie Marcus, the medtech ana ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 28, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R ...

Medtronic plc (NYSE:MDT) 5th Annual Evercore ISI HealthCONx Conference Call Summary Company Overview - **Company**: Medtronic plc - **Date**: November 29, 2022 - **Participants**: Geoff Martha (CEO), Karen Parkhill (CFO), Vijay Kumar (Evercore ISI) Key Points Financial Performance - Medtronic reported a fiscal Q2 topline miss but achieved EPS at the high end of the range, indicating effective cost management despite revenue challenges [4][5] - The company revised its guidance downward for the second half of FY2023 due to slower recovery in procedures and supply chain issues [4][12] Business Transformation and Growth Drivers - Medtronic is undergoing significant changes to its operating model and culture to enhance competitiveness and drive growth [5][9] - Key growth areas identified include: - **Cardiac Rhythm Management**: Consistently outperforming [8] - **Structural Heart**: Strong performance noted [8] - **Neurovascular, ENT, and Cardiac Surgery**: All showing positive results [8] - **Diabetes and Surgical Robotics**: Positioned for strong growth in the coming years [9][10] Supply Chain and Market Recovery - Supply chain challenges were more prolonged than anticipated, particularly affecting the Surgical Innovations business [12][13] - The company expects normalization of supply chain issues throughout FY2023 [16] - Recovery in elective procedures is uneven across markets, with notable strength in orthopedics and spine [18][19] China VBP Impact - Approximately 15% to 20% of the guidance reduction is attributed to changes in provincial tenders in China, which were expected to occur later [22][24] - The neurovascular business in China is significant, with expectations for future growth despite recent declines [26] Product Pipeline and Innovations - New product launches, including the Evolut FX valve and advancements in robotic surgery, are anticipated to drive growth in the second half of FY2023 [28][29] - The Hugo robotic system is gaining traction, with positive feedback from surgeons and competitive performance noted at recent conferences [34][35] Diabetes Segment - The 780G system is expected to replicate international success in the U.S. market, driven by strong patient feedback and clinical results [53][54] - Medtronic is investing in a robust pipeline for diabetes management, including the Simplera sensor, which is a zero-calibration device [55][57] Financial Outlook and Capital Allocation - FX headwinds are projected to impact FY2024 EPS by approximately $0.36, equating to about 7% growth off current guidance [59] - Medtronic is balancing shareholder returns through dividends and share repurchases while investing in long-term growth drivers [70][72] Strategic Focus - Recent divestitures in non-core areas are part of a strategy to streamline operations and focus on high-growth segments [73][74] - The company aims for a higher level of growth through strategic portfolio management and capital allocation [74] Additional Insights - Medtronic is committed to maintaining a strong balance sheet and dividend during challenging market conditions [5] - The company is focused on enhancing its competitive position through innovation and operational improvements [9][10]